Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT ODT versus DONEPEZIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT ODT versus DONEPEZIL HYDROCHLORIDE.
ARICEPT ODT vs DONEPEZIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine concentration in the synaptic cleft of the central nervous system.
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
Alzheimer's disease: Initial 5 mg orally once daily at bedtime for 4-6 weeks, increase to 10 mg once daily. Maximum dose 10 mg/day.
None Documented
None Documented
Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations.
Terminal elimination half-life approximately 70 hours (range 50-100 hours), allowing once-daily dosing; steady-state reached in 14-21 days
Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor
Renal (26% unchanged), fecal (57%, primarily as metabolites via biliary excretion)
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor